S&P Global set a GBX 1,500 ($19.54) price target on GlaxoSmithKline plc (LON:GSK) in a research report report published on Wednesday. The brokerage currently has a sell rating on the stock.
Other analysts have also issued reports about the company. UBS AG set a GBX 1,600 ($20.84) price objective on GlaxoSmithKline plc and gave the stock a neutral rating in a research report on Thursday, April 27th. Deutsche Bank AG restated a hold rating on shares of GlaxoSmithKline plc in a research report on Wednesday, July 19th. J P Morgan Chase & Co restated a neutral rating on shares of GlaxoSmithKline plc in a research report on Monday. Morgan Stanley restated an equal weight rating and set a GBX 1,700 ($22.15) target price on shares of GlaxoSmithKline plc in a research report on Tuesday, July 18th. Finally, Shore Capital restated a hold rating on shares of GlaxoSmithKline plc in a research report on Thursday, July 20th. Four research analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have given a buy rating to the company. The company has a consensus rating of Hold and an average price target of GBX 1,731.04 ($22.55).
GlaxoSmithKline plc (LON:GSK) traded down 0.94% during trading on Wednesday, hitting GBX 1531.00. 9,355,119 shares of the stock traded hands. The stock’s market cap is GBX 74.80 billion. The company has a 50-day moving average price of GBX 1,644.51 and a 200 day moving average price of GBX 1,627.71. GlaxoSmithKline plc has a one year low of GBX 1,446.50 and a one year high of GBX 1,745.56.
ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline plc (LON:GSK) Given a GBX 1,500 Price Target at S&P Global” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/07/27/glaxosmithkline-plc-longsk-given-a-gbx-1500-price-target-at-sp-global.html.
The business also recently disclosed a dividend, which will be paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th will be paid a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 10th.
In related news, insider Victoria Whyte sold 4,820 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of GBX 1,693 ($22.06), for a total transaction of £81,602.60 ($106,308.75). Also, insider Patrick Vallance bought 861 shares of the firm’s stock in a transaction that occurred on Friday, July 14th. The shares were acquired at an average cost of GBX 1,618 ($21.08) per share, for a total transaction of £13,930.98 ($18,148.75). In the last quarter, insiders have bought 3,150 shares of company stock worth $5,054,075.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.
